Lawrence holds 10 awarded patents, which include protecting anticancer small molecule technology licensed to GLG Pharma (STAT3 inhibitors) and Debiopharm (disruptors of the Rb-Raf protein-protein interaction). Most recently, a series of multitargeting dual bromodomain-kinase inhibitors was licensed to Aptose Biosciences. Lawrence has published over 100 peer reviewed papers and 15 review articles in organic and medicinal chemistry and anticancer drug design.
Nicholas Lawrence, a professor in the USF department of oncologic sciences and a senior member of the drug discovery department at Moffitt Cancer Center. Lawrence?s work was instrumental in an agreement between Moffitt and Aptose Biosciences (NASDAQ: APTO) that is expected to help Aptose expand its pipeline for cancer-fighting therapies. http://www.bizjournals.com/tampabay/news/2016/12/...of.html?ana=yahoo
----------- Jeder ist für sein Handeln selbst verantwortlich. Keine Kaufs-/Verkaufsempfehlung !!! Im Unterschied zur Straßenbahn wird an der Börse zum Ein- und Aussteigen nicht geklingelt.